Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fasting FFA and Glucose on Insulin Secretion
NCT03998709Phase 4Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 cohorts), sponsored by Mayo Clinic. Primary endpoints: First phase of Insulin secretion in response to manipulation of fasting FFA and glucose and Second phase of Insulin secretion in response to manipulation of fasting FFA and glucose. Planned start Feb 2020; status: withdrawn.
Beyond the preview
Go deeper on NCT03998709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998709.